ACAD250117C50000
- 0.05
- 0.000.00%
ACADIA Pharmaceuticals Newsroom
ACADIA Pharmaceuticals (ACAD) Receives a Buy From RBC Capital
Mizuho Securities Maintains ACADIA Pharmaceuticals(ACAD.US) With Hold Rating, Announces Target Price $20
Analysts Conflicted on These Healthcare Names: Avadel Pharmaceuticals (AVDL) and ACADIA Pharmaceuticals (ACAD)
Further Weakness as ACADIA Pharmaceuticals (NASDAQ:ACAD) Drops 5.2% This Week, Taking Five-year Losses to 61%
ACADIA Pharmaceuticals Analyst Ratings
Guggenheim Downgrades ACADIA Pharmaceuticals(ACAD.US) to Hold Rating, Announces Target Price $20
Express News | ACADIA Pharmaceuticals Inc : Guggenheim Cuts Target Price to $20 From $23
Acadia Pharmaceuticals Downgraded to Neutral From Buy at Guggenheim
Top Midday Gainers
ACADIA Pharmaceuticals Up Over 11%, on Pace for Largest Percent Increase Since December 2023 -- Data Talk
Acadia Pharmaceuticals, FTAI Aviation And Other Big Stocks Moving Higher On Tuesday
Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday
Biggest Stock Movers Tuesday: VSTM, ACAD
Acadia Pharmaceuticals Set to Join S&P SmallCap 600
Express News | S&P Dow Jones Indices: ACADIA Pharmaceuticals to Replace Independent Bank Group in S&P Smallcap 600
Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | ACADIA Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Express News | ACADIA Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million